AcouSort (ACOU) Q2 2025 earnings summary

Executive summary

• Strengthened presence in flow cytometry and cell therapy through new collaborations and business development activities in Q2 2025.

• Rights issue completed, raising MSEK 24.9 before costs, providing financial stability for ongoing development and partnerships.

• Participation in major industry conferences and selection for the European Pavilion at BIO 2025, enhancing visibility and networking.

• Continued focus on OEM partnerships and integration of automated sample processing technology in diagnostics and cell therapy.

Financial highlights

• Q2 2025 net sales increased to TSEK 1,551 from TSEK 961 year-over-year; H1 2025 net sales were TSEK 3,146, up from TSEK 2,318.

• Q2 2025 result before tax improved to TSEK -2,809 from TSEK -4,714; H1 2025 result before tax was TSEK -6,831, compared to TSEK -8,443.

• Result per share for H1 2025 was SEK -0.41, an improvement from SEK -0.57 year-over-year.

• Equity ratio rose to 81% as of June 30, 2025, up from 61% a year earlier.

• Cash and cash equivalents at quarter-end were TSEK 16,675, supporting operations into 2027.

Outlook and guidance

• Focus remains on expanding OEM partnerships and advancing integration of technology in diagnostics, cell therapy, and flow cytometry.

• Financial position and ongoing collaborations expected to support business development at least into 2027.

• Continued participation in key industry events and scientific publications to drive growth and innovation.